In an early clinical trial in the U.S., most women with hard-to-treat ovarian cancer given a low dose of cell therapy candidate liraltagene autoleucel,…
News
Anito-cel (anitocabtagene autoleucel), a cell therapy in clinical development as a potential treatment for myeloma, may be less likely to cause side effects than…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to an experimental treatment from Imviva Biotech that’s being tested in people…
A first-in-human clinical trial will launch in the coming months to test GTB-5550, an immune therapy from GT Biopharma that’s designed to treat various types…
A team of scientists at the University of Cincinnati Cancer Center is embarking on a series of tests to evaluate an experimental immune-modulating treatment strategy…
A long-lasting gel used to help protect the bowel during radiation therapy for prostate cancer may be successfully used in women with gynecological cancers…
A treatment regimen combining Darzalex Faspro (daratumumab and hyaluronidase-fihj) with three other medications is now approved in the U.S. for all people newly diagnosed…
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to QTX-2101, an oral formulation of an approved chemotherapy drug, as a potential treatment…
A first-in-human clinical trial testing RMC-5127, an experimental treatment for people with pancreatic cancer and other cancers marked by a specific genetic mutation called…
The majority of patients with recurrent glioblastoma remain alive following treatment with an experimental immune-modulating combination, according to a clinical trial update from Immunitybio.
